Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. 1) GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

JULY 15, 2021

JJIPO@Monash was originally launched in 2018 to provide crucial support to researchers and companies in the Victorian life-science sector as part of the Government’s commitment to the medical technologies and pharmaceuticals sector – one of eight priority growth sectors.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. President and Chief Executive Officer of Tonix Pharmaceuticals. 2018) PLoS One. About Tonix Pharmaceuticals Holding Corp. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Drug Target Review

MAY 23, 2023

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities. link] Zhu et al.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

DECEMBER 17, 2020

Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Karydas is chief financial officer at Syndax Pharmaceuticals. Sucampo Pharmaceuticals and Histogenics Corporation.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 21] In August 2017, it was announced that Cerecor had sold its rights to aticaprant to Janssen Pharmaceuticals. [22] 30 January 2018. nM vs. 24.0 nM vs. 24.0

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Drug Target Review

JANUARY 5, 2024

The need to identify new drug targets and candidate active pharmaceutical ingredients (APIs) for treating PAM is increasing, as the geographic range of N. In particular, an ethylene glycol molecule (EDO403) was observed to be stably (and non-covalently) bound within the conventional nucleotide-binding pocket of Nf Ga7 ( Figure 2a ).

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Pharma Data

SEPTEMBER 2, 2020

Fenebrutinib is designed to be a highly selective small molecule and is the only reversible (non-covalent) BTK inhibitor currently in Phase III development in MS. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. In 2019, Roche invested CHF 11.7

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

Agency IQ

NOVEMBER 27, 2023

In 2018, NDMA was first detected in the active pharmaceutical ingredient (API) for valsartan, a blood pressure drug. Investigations revealed that nitrosamine impurities were found in pharmaceutical products due to reasons outside API synthesis , through re-use of chemical precursors containing leftover contaminants.

Regulations 40

Regulations Production FDA Marketing 40

Agency IQ

AUGUST 11, 2023

BY KARI OAKES AUG 7, 2023 10:20 PM CDT Quick background on nitrosamines in pharmaceutical products Nitrosamines are a large and diverse class of chemicals, with more than 300 different structurally distinct species known today. In 2018, NDMA was first detected in the active pharmaceutical ingredient (API) for valsartan, a blood pressure drug.

FDA 40

FDA Science Production Regulations 40

New Drug Approvals

APRIL 18, 2023

H]Cl.NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3 AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. 2018 Jul;40(1):303-308. Molecular Weight 349.47 Appearance Solid Formula C 21 H 27 N 5 CAS No. 2309699-17-8 SMILES [H]Cl.[H]Cl.[H]Cl.NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3

Clinical Trials 52

Clinical Trials Virus Small Molecule Trials 52

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. 2018 ; Ding et al., 2017 ; Ilievski et al.,

Small Molecule 62

Small Molecule DNA Disease Trials 62

Metabolite Tales Blog

MAY 12, 2023

Now >20% of all commercialised medicines in the pharmaceutical industry contain a fluorine atom [2]. Even newer from the pharma benches are 12 small molecule drugs highlighted by Chris de Savi [4], whose structures were first disclosed at the ACS and AACR meetings in Q1 2023. Benjamin M. Bourgeois, James A. Abouda, Kahari J.

Drugs 52

Drugs Small Molecule FDA Approval Metabolic Stability 52

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Pharmaceuticals 52

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Would we wind down and exit, or chart some different path?

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

Agency IQ

OCTOBER 6, 2023

CDER is the FDA office in charge of reviewing pharmaceuticals and therapeutic biologics. All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). Amanda Conti, AgencyIQ What kind of biologic products entered the market?

FDA 52

FDA Biosimilars Science Drugs 52

The Pharma Data

JANUARY 18, 2021

ZTlido ® was approved by the FDA on February 28, 2018. SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc. for the treatment of post-herpetic neuralgia. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 13, 2021

14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. CHATHAM, N.J.,

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 1 , 33–43 (2018).

Small Molecule 127

Small Molecule Drugs Immune Response Targeted Protein Degradation 127

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% Pharmaceuticals business operating income. In the first quarter, business operating income (BOI) of Pharmaceuticals decreased 4.6% This increase mainly reflected the improvement of the Pharmaceuticals gross margin ratio (from 74.9% 9.0 . %. .

Vaccine 52

Vaccine Production FDA Disease 52

Agency IQ

NOVEMBER 3, 2023

Synthetic biotics have been engineered to perform a variety of functions: “ Several classes of effectors have been engineered into bacteria, including enzyme pathways that metabolize disease-causing toxins, production of protein effectors, and production of small-molecule effectors,” according to a recent article on the topic.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

APRIL 7, 2023

About BRAFTOVI + MEKTOVI BRAFTOVI is an oral small molecule BRAF kinase inhibitor and MEKTOVI is an oral small molecule MEK inhibitor which target key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK). Ono Pharmaceutical Co. The approval was based on results from the BEACON CRC trial.

FDA 40

FDA FDA Approval Small Molecule Drugs 40

The Pharma Data

DECEMBER 2, 2020

Previously, the company announced positive results of the previous Phase IIa induction study in UC in September 2018. The drug is a small-molecule inhibitor of the S. eTheRNA – Belgium-based eTheRNA immunotherapies NV entered into a strategic agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd.

Licensing 52

Licensing Licensing DNA Drugs 52

Drug Target Review

APRIL 25, 2025

3 These models are pivotal for offering key predictive insights into the clearance of metabolically stable small molecules, maintaining phase I and II metabolic activities for up to four weeks. 9,10 According to IQ-MPS recommendations, liver-on-chip systems can differentiate between toxic and non-toxic small molecule analogues.

Clinical Development 52

Clinical Development Small Molecule Drugs FDA Approval 52

New Drug Approvals

MAY 27, 2025

PATENT Journal of the American College of Cardiology (2018), 72(5), 489-497 American Heart Journal (2022), 253, 20-29 Expert Opinion on Investigational Drugs (2020), 29(1), 1-4 EP4119137 WO2016165014 WO2023108146 EP-2170050-B1 US-9737503-B2 US-4968717-A EP-0231003-A2 [1]. 2018 Jul 31;72(5):489-497. Stambler BS, et al.

Pharmaceuticals 67

Pharmaceuticals Small Molecule Pharmacokinetics Treatment 67

New Drug Approvals

MAY 11, 2025

11] History Omaveloxolone is a second generation member of the synthetic oleanane triterpenoid compounds and in clinical development by Reata Pharmaceuticals. 2018 May 1;141(5):1390-1403. 2018 Nov 10;6(1):15-26. 2] [5] It is taken by mouth. [2] 9] SYNTHESIS PATENT Sheikh, AY et al. 2] [5] It is taken by mouth. [2] 2022.952950.

FDA 57

FDA FDA Approval Disease Production 57

New Drug Approvals

APRIL 30, 2025

Formula C 33 H 31 F 2 N 3 O 7 Kanitinib PFR26A3AWM GTPL12865 CX1003 CX-1003 6-[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxyquinolin-7-yl]oxyhexanoic acid CANLITINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.

Small Molecule 62

Small Molecule Clinical Trials Production Pharmaceuticals 62

Codon

MAY 29, 2025

While small-molecule drugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. The pharmaceutically promising aspect of this deadly protein is that it can relax muscles.

Drugs 109

Drugs DNA RNA Laboratories 109

New Drug Approvals

JUNE 2, 2025

FIRMONERTINIB is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications. PATENT CN110606842 WO2019238103 PAPER [link] NCT Number Sponsor Condition Start Date Phase NCT02973763 Allist Pharmaceuticals, Inc. Shi, et al.

Production 62

Production Clinical Trials Trials International 62